In India, the Russian-developed Corona Vaccine Sputnik V has been approved for emergency use. This is the third vaccine for the coronavirus to be approved after Kovshield (Serum Institute of India) and Kovaxin (Bharat Biotech).
The Sputnik V vaccine, developed by Moscow's Gamale National Research Institute of Epidemiology and Microbiology, uses two different viruses that cause the common cold (adenovirus) in humans. Adenovirus becomes weak so it cannot replicate in humans and cannot cause disease.
Let me tell you that this vaccine is also modified. For this reason, the vaccine provides a code for making the coronavirus spike protein. The purpose of this process is to ensure that when the actual virus tries to infect the body, it can mount an immune response in the form of antibodies.
Sputnik uses a different vector for each of the two shots during vaccination. According to this Russian Direct Investment Fund (RDIF), the same methods are used for both shots. It provides immunity with a longer duration than other vaccines. A difference of 21 days is required for both shots.
Sputnik V (liquid) is stored at a temperature of minus 18 ° C. However, its dried form can be stored at 2–8 ° C. This does not require investing in cold-chain infrastructure. According to the RDIF, Sputnik V has been approved for the use of more than 150 crore people in 55 countries. The vaccine is proposed to be priced below $ 10 per shot. Although its price in India has not been decided.
Dr. Reddy's labs based in Hyderabad sought government approval for the vaccine in India. RDIF partnered with Dr. Reddy's in September 2020 to conduct clinical trials in the country. On Monday, the Subject Expert Committee (SEC) of the Drugs Controller General of India took the Sputnik V application for Emergency Use Authority and moved on. DCGI previously sought additional data from the drug manufacturer.
Five other Indian companies have partnered with RDIF for Sputnik V. These include Gland Pharma, Hetero Biopharma, Virchow Biotech, Panacea Biotech, and Stellis Biopharma, Bangalore-based Strides Pharma Science's bioceramic. It is expected from their partnerships that India's capacity to manufacture this vaccine will exceed 60 million.
The ASI team reached the campus on Thursday morning for an investigation into the Gyanvapi campus
Corona infection rate crosses 17%, can schools be closed again in Delhi?
Concerns about school-going children have increased amid rising COVID-19 cases in Delhi. However,
A tweet by Shiv Sena leader Sanjay Raut has once again increased the political stir in Maharashtr
Pakistan has made a U-turn on its decision not to play the T20 World Cup against India. Now, repo
Kangana Ranaut has been speaking openly about nepotism for a long time. From Karan Johar to Hrith
Sri Lanka is passing through a bad phase of economic and political crisis. The people of the coun
The air quality in the national capital Delhi and the entire NCR has once again reached the sever
In the fourth Test match to be played between India and England from February 23 at JSCA Stadium,
India COVID Update: The country got control over Corona, and the positive rate is decreasing rapidly
There is a decrease in the cases of corona in the country. According to the report presented by t
Sanju Samson-led Rajasthan Royals have had a great performance so far in IPL 2024. The Rajasthan
